Thromb Haemost 1992; 67(03): 306-309
DOI: 10.1055/s-0038-1648437
Original Articles
Schattauer GmbH Stuttgart

Double-Blind, Randomized Comparison of Systemic Continuous Infusion of 0.25 Versus 0.50 mg/kg/24 h of Alteplase over 3 to 7 Days for Treatment of Deep Venous Thrombosis in Heparinized Patients: Results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) Trial[*]

H Bounameaux
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
J D Banga
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
E Bluhmki
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
S Coccheri
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
J N Fiessinger
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
W Haarmann
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
D Lockner
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
F Mahler
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
J Ninet
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
P A Schneider
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
A de Torrente
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
J van der Meer
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
,
and R Verhaeghe
Geneva, Switzerland; Utrecht, The Netherlands; Bologna, Italy; Paris, France; Huddinge, Sweden; Bern, Switzerland; Lyon, France; La Chaux-de-Fonds, Switzerland; Groningen, The Netherlands; and Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 02 July 1991

Accepted after revision 13 September 1991

Publication Date:
03 July 2018 (online)

Summary

Thirty-two patients with acute, proximal-vein thrombosis were treated with heparin and alteplase (0.25 versus 0.5 mg/kg/24 h during 3-7 days) in a randomized, double-blind, multicenter, European (ETTT) trial. The treatment resulted in a decrease of the venographic Marder’s score from 18 (6-25) to 13 (2-24) units (median, range) in Group I (0.25 mg/kg/24 h, n = 15, median decrease 3.0, p = 0.32) and from 17.5 (3-33) to 15.5 (0-27) in Group II (0.5 mg/kg/24 h, n = 16, median decrease 4.0, p = 0.23). Comparison of the sequential venograms could be performed in 14 cases of Group I and in 15 cases in Group II. A minority of patients showed substantial partial recanalization of the initially obstructed veins on the control venogram (one in each treatment group) and most of the control venograms showed

Thus, the results of the ETTT trial show that the used low dosages of alteplase administered intravenously over 3-7 days in heparinized patients cannot be recommended as a treatment for patients with deep venous thrombosis of lower limbs and/or pelvis. Further studies are needed to define a more suitable dosage regimen of alteplase in this indication.

Complete list of the participating centers and investigators at the end of the paper


 
  • References

  • 1 National Institutes of Health Consensus Development Conference. Thrombolytic therapy in thrombosis: A National Institutes of Health Consensus Development Conference. Ann Intern Med 1980; 93: 141-144
  • 2 Duckert F. Thrombolytic therapy. Semin Thromb Hemostas 1984; 10: 87-103
  • 3 Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebo-graphically documented acute deep venous thrombosis. Am J Med 1984; 76: 393-397
  • 4 Jacobsen B. Thrombolytic treatment in venous thromboembolism. In: Controversies in the Management of Venous Disorders. Eklöf B, Gjöres JE, Thulesius O, Bergqvist D. (eds). Butterworths; London: 1989. pp. 116-126
  • 5 Van de Loo JCW, Kriessmann A, Trübenstein G, Knoch K, de Swart CAM, Asbeck F, Marbet GA, Schmitt HE, Sewell AF, Duckert F, Theiss W, Ritz R. Controlled multicenter pilot study of urokinaseheparin and streptokinase in deep vein thrombosis. Thromb Haemostas 1983; 50: 660-663
  • 6 Verstraete M, Collen D. Thrombolytic therapy in the eighties. Blood 1986; 267: 1529-1541
  • 7 Verhaeghe R, Besse P, Bounameaux H, Marbet GA. Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/ or pelvis. Thromb Res 1989; 55: 5-11
  • 8 Goldhaber SZ, Meyerovitz MF, Green D, Vogelzang RL, Citrin P, Heit J, Sobel M, Wheeler HB, Plante D, Kim H, Hopkins A, Tufte M, Stump D, Braunwald E. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990; 88: 235-240
  • 9 Turpie AGG, Levine MN, Hirsh J, Ginsberg JG, Cruickshank M, Jay R, Gent M. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. Chest 1990; 97 Suppl. 172 S-175 S
  • 10 Zimmermann R, Horn A, Harenberg J, Diehm C, Müller-Bühl U, Kübler W. Thrombolysetherapie der tiefen venösen Thrombose mit rt-PA. Klin Wschr 1988; 66 Suppl. XII: 137-142
  • 11 Zimmermann R, Gürsoy A, Horn A, Harenberg J, Diehm C, Kübler W. Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator. Semin Thromb Hemostas 1991; 17: 48-54
  • 12 Marder VJ, Soulen RL, Atichartakam V, Budzinsky AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative veno-graphic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-1029
  • 13 Bounameaux H, Prins TR, Schmitt HE, Schneider PA. Venography of the lower limbs: Pitfalls of the gold standard. Eur Radiol (submitted).
  • 14 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-246
  • 15 Eliakim R, Foldes J, Mogle P. Extensive subcutaneous hemorrhage following ultrasonic examination of the abdomen. Isr J Med Sei 1983; 19: 644-645
  • 16 Zimmermann R, Seifried E, Schramm W, Haarmann W, Bluhmki E. rt-PA thrombolysis of deep vein thrombosis with different dosages. Results of a prospective multicenter study. Thromb Haemostas 1991; 65: 1132 (Abstr. 1571)